MUC1 - Search News

MUC1, PDS Biotech and national cancer institute

PDS Biotech gets IND application clearance for colorectal cancer treatment

PDS Biotechnology (NASDAQ:PDSB) said on Thursday it received U.S. FDA clearance for its Investigational New Drug application to treat metastatic colorectal carcinoma in patients who failed previous treatment.

Markets Insider · 1d

PDS Biotech announces FDA clearance of IND apprlication for Versamune MUC1 combo

PDS Biotechnology (PDSB) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application filed in

Precision Medicine Online · 1d

PDS Biotech Cleared to Begin Trial of Immunotherapy Combo in MUC1-Positive Colorectal Cancer

The NCI will lead the trial of the firm's Versamune MUC1 immunotherapy and its antibody-drug conjugate PDS01ADC.

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer InstituteSecondVersamune®platform candidate ...

Nature25d

Mucins in cancer: function, prognosis and therapy

Expression of the transmembrane mucin MUC1 is upregulated in response to chronic inflammation. Aberrant overexpression of transmembrane mucins is associated with diverse human carcinomas and ...

Hosted on MSN6mon

New Antibody Detection Technique Offers Breakthrough in Early Pancreatic Cancer Diagnosis

The glycosylation pattern of TA-MUC1 in tumors differs from its normal form, making it a key indicator of the disease. Related News | How Does AI Help In Early Detection and Treatment Of Cancer?

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

MUC1, PDS Biotech and national cancer institute

Trending now